Skip to main content

Table 4 Summary of the major characteristic molecular features of ABC-DLBCL-NOS

From: Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review

Genetic Aberration: Gain of function

Genetic Aberration: Loss of function

Pathways: Upregulated/Gain

Pathways: Inhibited/Loss

Study

MyD88 L265P (Mut) MyD88 (other)

 

TLR/MyD88 NF-κB, IRF4

IRF7/IFNβ (Type 1 interferon)

[16–18]

CD79A, CD79B (Mut)

 

B-cell receptor NF-κB, IRF4,

IRF7/IFNβ (Type 1 interferon)

[16, 17]

CARD11 (Mut)

 

NF-κB, IRF4

IRF7/IFNβ (Type 1 interferon)

[16–18]

 

TRAF3 (Del/Mut)

Canonical NF-κB (p65/p50) and non-canonical NF-κB (p52/RELB) signaling, IRF4

IRF7/IFNβ (Type 1 interferon)

[16–18, 26, 27, 160]

TRAF2 (Del/Mut)

SPIB (Tx/Mut)

 

CARD11/NF-κB, IRF4

IRF7/IFNβ (Type 1 interferon)

[13, 16, 17, 87, 90]

REL (Ampl)

 

_

_

[619]

BCL2 (Tx/Ampl/Methyl)

 

BCL2

Pro-apoptotic signaling

[362]

MYC (Tx/Ampl/Methyl)

 

c-MYC

 

[87, 107]

BCL6 (Tx/Ampl/Methyl)

 

BCL6

BLIMP1, CREBBP; EP300

[87, 93, 148, 386, 612, 620]

MEF2B (Mut)

 

BCL6

BLIMP1, CREBBP; EP300

[13, 16, 17, 28]

STAT3 (Mut)

 

IL6/10, JAK/STAT3

 

[307, 316]

??

??

STAT1

 

[470]

FOXP1 (Ampl)

 

Wnt/β-catenin

TP53/Pro-apoptotic signaling

[13, 621, 622]

 

TP53 (Del/Mut)

 

TP53 and TP73Pro-apoptotic signaling

[16, 17, 155, 614

TP73 (Del)

 
 

B2M (Del/Mut)

 

B2M, HLA-I complex

[16, 17, 615, 616]

 

CD58 (Del/Mut)

 

CD58, HLA-I complex

[16, 17, 615, 616]

 

MLL2, MLL3 (Mut)

 

MLL2, CREBBP; EP300

[12, 16, 17, 20]

 

CREBBP; EP300 (Del/Mut)

BCL6, STAT3, HSP90

CREBBP; EP300, BLIMP1, TP53

[17–19, 386, 388, 392]

 

CDKN2A/B (Del/Methyl)

 

P16INK4a/pRB p14ARF/TP53

[13, 120]

 

TNFAIP3 (Del/Mut)

NF-κB, IRF4

A20

[13, 16–18]

 

PRDM1 (Del/Mut)

 

BLIMP1

[13, 16, 17]

  1. Overlapping molecular features of ABC-DLBCL and PMLBCL are marked as italic and those of GCB- and ABC-DLBCL are marked as bolditalic. Overlapping molecular features of PMLBCL, GCB-DLBCL and ABC-DLBCL are marked as bold. Normal letters refer to genetic aberrations that contribute to DLBCL pathogenesis, regardless of subtype.
  2. DLBCL diffuse large B cell lymphoma, ABC activated B cell-like, GCB germinal center B cell-like, PMLBCL primary mediastinal (thymic) large B-cell lymphomas, Del deleted/deletions, Mut mutated/mutations, Ampl amplified/amplification, Tx translocations, BCL2 B-cell lymphoma protein 2, BCL6 B-cell lymphoma protein 6, NF-κB nuclear factor-kappa B, TLR Toll like receptor, MyD88 myeloid differentiation primary response 88, CARD11 caspase recruitment domain family, member 11, IRF4 interferon-regulatory factor 4, CREBBP CREB-binding protein, EP300 E1A-binding protein p300, EZH2 enhancer of zeste homologue 2, PRDM1/ BLIMP1 B-lymphocyte-induced maturation protein 1, TNFAIP3 tumor necrosis factor, alpha-induced protein 3, TRAF TNF-receptor-associated factor, MLL myeloid/lymphoid or mixed-lineage leukemia, CDKN1A cyclin-dependent kinase inhibitor 1A, MDM2 murine double minute E3 ubiquitin protein ligase 2, STAT signal transducer and activator of transcription, FOXP1 forkhead box P1, IRF7 interferon-regulatory factor 7, IFNβ interferon beta, MEF2B myocyte enhancer factor 2B, FAS TNF receptor superfamily, member 6, HLA Histocompatibility antigen, domains alpha
Back to article page

Molecular Cancer

ISSN: 1476-4598